Fosfomycin for treating Escherichia coli UTIs: Results from a tertiary hospital

---

Original Article

Author Details : Saurabh Chhotalal Norris, Monika Lavjibhai Mavani, Dhwani Vasantkumar Patel, Himani Bhardwaj Pandya*, Tanuja Bakul Javadekar

Volume : 10, Issue : 3, Year : 2024

Article Page : 226-229

https://doi.org/10.18231/j.ijmmtd.2024.039

Suggest article by email

Get Permission

---

Abstract

Background: Urinary tract infections (UTIs) arise due to the infiltration of microorganisms into the urinary system. The rising incidence of antibiotic resistance among UTI pathogens has narrowed the range of effective treatment options. Fosfomycin has been recognized as a potential alternative in the face of increasing resistance.
Aim and Objective: This research focuses on evaluating the in vitro effectiveness of Fosfomycin against gram-negative bacteria isolated from urinary tract infections (UTIs)
Materials and Methods: This retrospective study was carried out at the tertiary care hospital in Vadodara, Gujarat from 1st Jan 2022 to 31st Oct 2022. Out of 256 urine cultures that tested positive for microorganisms, 125 isolates (62.8%) were identified as Escherichia coli and were included in the study. Standard laboratory techniques were used for bacterial identification, and the VITEK 2 compact system was employed for antimicrobial sensitivity testing. The sensitivity of Fosfomycin was assessed using the
disc diffusion technique with a 200 g disc (Himedia), and the results were interpreted by measuring the zone of inhibition.
Results: Fosfomycin showed a sensitivity rate of 96% against Escherichia coli. Among extended-spectrum beta-lactamase (ESBL)-producing strains, Fosfomycin demonstrated a sensitivity rate of 91.4%.
Conclusion: Fosfomycin presents a valuable option for treating UTIs, particularly those caused by Escherichia coli, including strains that produce ESBLs.

Keywords: Ecoli, Fosfomycin, ESBL

How to cite : Norris S C, Mavani M L, Patel D V, Pandya H B, Javadekar T B, Fosfomycin for treating Escherichia coli UTIs: Results from a tertiary hospital. IP Int J Med Microbiol Trop Dis 2024;10(3):226-229

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.